ArticlebioRxiv : the preprint server for biology2025
HPV16 recruitment of SMARCAL1 to viral and host replication forks is required for the viral life cycle.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-risk human papillomaviruses (HR HPVs) are responsible for around 5% of the world's cancer burden. Activation and interaction with the host DNA damage response (DDR) promotes the HPV16 life cycle. This study demonstrates a crucial interaction between HPV16 and SMARCAL1, a protein involved in the stabilization of stalled DNA replication forks. SMARCAL1 can complex with E2, is recruited to E1-E2 replicating DNA, and SMARCAL1 knockdown reduces the fidelity of E1-E2 mediated DNA replication in C33a cells but does not alter replication levels. SMARCAL1 is recruited to the HPV16 genome in HPV16-immortalized foreskin keratinocytes (HFK+HPV16), and Importance: HPV16 is responsible for the majority of HPV+ cancers, contributing to 54% of cervical cancers and ∼90% of HPV+HNSCC. Integration of viral genomes into host DNA can promote cervical cancer progression and correlates with poor prognosis in HPV-associated HNSCC, where around 70% of HPV+ cancers contain episomal viral genomes. Developing effective antiviral therapies requires a deeper understanding of the interplay between viral replication and host DNA damage response (DDR) pathways. This report demonstrates that SMARCAL1 is essential for HPV16 replication and keratinocyte proliferation and that its depletion leads to replication stress, DNA damage, and viral genome integration. This work underscores the delicate balance between viral exploitation of the host DDR and the risk of genome instability. These insights contribute to the broader understanding of HPV pathogenesis and may inform the development of therapeutic strategies targeting viral replication to prevent disease progression and improve clinical outcomes in HPV-associated cancers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.